Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Double-Blind, Parallel Design Study to Compare the Effectiveness of Eplerenone Versus Atenolol in Reversing the Remodeling of Resistance Arteries in Subjects With Mild to Moderate Primary Hypertension

NCT00147563 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT00147563
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00147563 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Double-Blind, Parallel Design Study to Compare the Effectiveness of Eplerenone Versus Atenolol in Reversing the Remodeling of Resistance Arteries in Subjects With Mild to Moderate Primary Hypertension
Lead sponsor
Pfizer
Phase
Phase 4
Overall status
Completed
Start date
October 31, 2003
Completion date
Not reported
Enrollment
34
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hypertension